Sunflower Pharmaceutical Group Co.,Ltd (SHE:002737)
China
· Delayed Price · Currency is CNY 13.68
+0.05 (0.37%)
Mar 10, 2026, 3:04 PM CST
SHE:002737 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 2,079 | 3,362 | 5,686 | 5,083 | 4,454 | 3,457 | Upgrade
|
| Other Revenue | 14.94 | 14.94 | 14.62 | 11.03 | 6.55 | 4.83 | Upgrade
|
| Revenue | 2,094 | 3,377 | 5,700 | 5,095 | 4,461 | 3,462 | Upgrade
|
| Revenue Growth (YoY) | -52.75% | -40.76% | 11.89% | 14.20% | 28.86% | -20.81% | Upgrade
|
| Cost of Revenue | 1,529 | 1,896 | 2,493 | 2,157 | 1,822 | 1,450 | Upgrade
|
| Gross Profit | 565.27 | 1,481 | 3,208 | 2,938 | 2,639 | 2,012 | Upgrade
|
| Selling, General & Admin | 620.59 | 854.08 | 1,839 | 1,751 | 1,643 | 1,192 | Upgrade
|
| Research & Development | 110.8 | 124.13 | 128.65 | 94.61 | 132.07 | 113.56 | Upgrade
|
| Other Operating Expenses | 125.76 | 42.25 | 60.82 | 69.4 | 65.56 | 51.03 | Upgrade
|
| Operating Expenses | 846.67 | 1,028 | 2,024 | 1,916 | 1,867 | 1,350 | Upgrade
|
| Operating Income | -281.4 | 452.83 | 1,184 | 1,022 | 771.33 | 661.92 | Upgrade
|
| Interest Expense | -3.16 | -3.56 | -5.97 | -9.73 | -10.19 | -7.39 | Upgrade
|
| Interest & Investment Income | 40.54 | 52.21 | 85.35 | 30.56 | 44.09 | 29.02 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.05 | 0.05 | -0.09 | 0.11 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -1.73 | 1.08 | -2.42 | -4.56 | -0.24 | -0.8 | Upgrade
|
| EBT Excluding Unusual Items | -245.71 | 502.61 | 1,260 | 1,039 | 805 | 682.74 | Upgrade
|
| Impairment of Goodwill | -4.8 | -4.8 | - | -15.83 | -27.22 | -36.73 | Upgrade
|
| Gain (Loss) on Sale of Investments | -4.33 | -12.99 | -16.39 | -19.31 | 2.67 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.6 | -0.24 | 3.23 | 7.43 | 47.77 | -5.41 | Upgrade
|
| Asset Writedown | -24.18 | -20.99 | -0.48 | -10.6 | -2.46 | -1.97 | Upgrade
|
| Other Unusual Items | 162.3 | 170.89 | 108.02 | 80.63 | 68.76 | 128.2 | Upgrade
|
| Pretax Income | -116.11 | 634.49 | 1,355 | 1,081 | 894.51 | 766.83 | Upgrade
|
| Income Tax Expense | 32.58 | 131.76 | 189.83 | 171.37 | 132.16 | 146.89 | Upgrade
|
| Earnings From Continuing Operations | -148.7 | 502.73 | 1,165 | 909.73 | 762.35 | 619.94 | Upgrade
|
| Minority Interest in Earnings | 20.37 | -10.69 | -45.8 | -42.51 | -57.61 | -35.48 | Upgrade
|
| Net Income | -128.33 | 492.05 | 1,119 | 867.22 | 704.74 | 584.45 | Upgrade
|
| Net Income to Common | -128.33 | 492.05 | 1,119 | 867.22 | 704.74 | 584.45 | Upgrade
|
| Net Income Growth | - | -56.03% | 29.05% | 23.06% | 20.58% | 3.37% | Upgrade
|
| Shares Outstanding (Basic) | 565 | 586 | 583 | 586 | 582 | 584 | Upgrade
|
| Shares Outstanding (Diluted) | 565 | 586 | 583 | 586 | 582 | 584 | Upgrade
|
| Shares Change (YoY) | -4.05% | 0.49% | -0.53% | 0.61% | -0.35% | 0.27% | Upgrade
|
| EPS (Basic) | -0.23 | 0.84 | 1.92 | 1.48 | 1.21 | 1.00 | Upgrade
|
| EPS (Diluted) | -0.23 | 0.84 | 1.92 | 1.48 | 1.21 | 1.00 | Upgrade
|
| EPS Growth | - | -56.25% | 29.73% | 22.31% | 21.00% | 3.09% | Upgrade
|
| Free Cash Flow | 229.28 | -400.27 | 740.52 | 1,822 | 746.92 | 957.14 | Upgrade
|
| Free Cash Flow Per Share | 0.41 | -0.68 | 1.27 | 3.11 | 1.28 | 1.64 | Upgrade
|
| Dividend Per Share | 0.500 | 0.500 | 1.500 | 1.000 | 0.700 | 0.350 | Upgrade
|
| Dividend Growth | -66.67% | -66.67% | 50.00% | 42.86% | 100.00% | -65.00% | Upgrade
|
| Gross Margin | 26.99% | 43.85% | 56.27% | 57.67% | 59.15% | 58.12% | Upgrade
|
| Operating Margin | -13.44% | 13.41% | 20.76% | 20.07% | 17.29% | 19.12% | Upgrade
|
| Profit Margin | -6.13% | 14.57% | 19.63% | 17.02% | 15.80% | 16.88% | Upgrade
|
| Free Cash Flow Margin | 10.95% | -11.85% | 12.99% | 35.77% | 16.74% | 27.65% | Upgrade
|
| EBITDA | -110.07 | 625.66 | 1,358 | 1,285 | 935.8 | 811.07 | Upgrade
|
| EBITDA Margin | -5.26% | 18.53% | 23.83% | 25.22% | 20.98% | 23.43% | Upgrade
|
| D&A For EBITDA | 171.33 | 172.83 | 174.82 | 262.65 | 164.47 | 149.15 | Upgrade
|
| EBIT | -281.4 | 452.83 | 1,184 | 1,022 | 771.33 | 661.92 | Upgrade
|
| EBIT Margin | -13.44% | 13.41% | 20.76% | 20.07% | 17.29% | 19.12% | Upgrade
|
| Effective Tax Rate | - | 20.77% | 14.01% | 15.85% | 14.77% | 19.16% | Upgrade
|
| Revenue as Reported | 2,094 | 3,377 | 5,700 | 5,095 | 4,461 | 3,462 | Upgrade
|
| Advertising Expenses | - | 217.86 | 1,078 | 1,068 | 115.37 | 127.86 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.